Dr Sandra N Seneshen, MD | |
301 Gordon Gutmann Blvd, Suite 401, Jeffersonville, IN 47130-3764 | |
(812) 282-0637 | |
(812) 283-6330 |
Full Name | Dr Sandra N Seneshen |
---|---|
Gender | Female |
Speciality | General Surgery |
Experience | 35 Years |
Location | 301 Gordon Gutmann Blvd, Jeffersonville, Indiana |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396730669 | NPI | - | NPPES |
200267780 | Medicaid | IN | |
196290271 | Other | IN | MEDICARE |
200267780A | Medicaid | IN | |
01053197A | Other | IN | STATE ID # |
7100447830 | Medicaid | KY | |
01053197B | Other | IN | CONTROLLED SUBSTANCE REG |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 01053197A (Indiana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Clark Memorial Hospital | Jeffersonville, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Rhn Clark Memorial Physician Practices Llc | 0840504114 | 85 |
News Archive
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants.
New, advanced techniques are needed that can mimic the normal blood supply that feeds natural bone to improve the viability and success of restorative procedures to replace damaged or diseased bone tissue using engineered constructs. A comprehensive review article describing the most promising strategies for vascularization of bone tissue substitutes is published in Tissue Engineering, Part B: Reviews, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.
Stem cell researchers at UCLA have uncovered for the first time why adult human cardiac myocytes have lost their ability to proliferate, perhaps explaining why the human heart has little regenerative capacity.
› Verified 7 days ago
Entity Name | Rhn Clark Memorial Physician Practices Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1083098651 PECOS PAC ID: 0840504114 Enrollment ID: O20150730011797 |
News Archive
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants.
New, advanced techniques are needed that can mimic the normal blood supply that feeds natural bone to improve the viability and success of restorative procedures to replace damaged or diseased bone tissue using engineered constructs. A comprehensive review article describing the most promising strategies for vascularization of bone tissue substitutes is published in Tissue Engineering, Part B: Reviews, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.
Stem cell researchers at UCLA have uncovered for the first time why adult human cardiac myocytes have lost their ability to proliferate, perhaps explaining why the human heart has little regenerative capacity.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Sandra N Seneshen, MD Po Box 776351 Suite 401, Chicago, IL 60677-6351 Ph: (502) 559-9337 | Dr Sandra N Seneshen, MD 301 Gordon Gutmann Blvd, Suite 401, Jeffersonville, IN 47130-3764 Ph: (812) 282-0637 |
News Archive
Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.
Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants.
New, advanced techniques are needed that can mimic the normal blood supply that feeds natural bone to improve the viability and success of restorative procedures to replace damaged or diseased bone tissue using engineered constructs. A comprehensive review article describing the most promising strategies for vascularization of bone tissue substitutes is published in Tissue Engineering, Part B: Reviews, a peer-reviewed journal from Mary Ann Liebert, Inc.
Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.
Stem cell researchers at UCLA have uncovered for the first time why adult human cardiac myocytes have lost their ability to proliferate, perhaps explaining why the human heart has little regenerative capacity.
› Verified 7 days ago
Dr. Steven Frederick Samuel, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 141 Quartermaster Ct, Jeffersonville, IN 47130 Phone: 502-583-7741 Fax: 502-290-9743 | |
Bardia Amirlak, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Riverpointe Plz Apt 702, Jeffersonville, IN 47130 Phone: 402-968-3528 | |
Dr. Wendell L Bailey, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 301 Gordon Gutmann Blvd Ste 401, Jeffersonville, IN 47130 Phone: 812-282-0637 Fax: 812-283-6330 | |
Dr. Matthew Edward Hennig, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 207 Sparks Ave Ste 201, Jeffersonville, IN 47130 Phone: 812-280-1419 Fax: 812-280-1451 | |
Dr. Daniel C Macmillan, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 301 Gordon Gutmann Blvd Ste 401, Jeffersonville, IN 47130 Phone: 812-282-0637 Fax: 812-283-6330 |